Amylin Obesity Drugs: Lilly And Novo’s Next Bet

I keep meeting people who did everything the new obesity playbook asked of them. They started the weekly shot, rearranged dinner, walked more, and still watched the scale flatten around month five. A friend described it as borrowing a ladder that stopped two rungs short of the roof. That is the quiet gap sitting underneath the GLP-1 boom, and it is exactly why amylin obesity drugs have moved from laboratory footnote to boardroom priority.

Eli Lilly and Novo Nordisk are not trying to erase the medicines that already rewired appetite for millions of patients. They are building a second lever. Amylin is a hormone released by the pancreas alongside insulin. It tells the brain that a meal has landed, slows the exit of food from the stomach, and trims the urge to keep eating. Same destination as a GLP-1, different road. In my view, that difference is the whole story.

Why Amylin Obesity Drugs Are The Next Lever

The first amylin medicine reached U.S. patients more than twenty years ago, as a mealtime add-on for people with diabetes who already used insulin. Adoption stayed thin. Multiple daily injections on top of insulin was a hard sell, even when the biology made sense. What changed is duration. The candidates now in development are long-acting. They are built to mimic the hormone in a sustained way and, in the versions drawing the most attention, to be taken once a week.

That schedule matters more than it sounds. A therapy people can fold into Sunday evening is a different product from a therapy that interrupts every meal. Metabolic researchers have been saying this for a while: biology that cannot survive real life does not scale. Weekly amylin analogs are an attempt to make an old signal usable.

Amylin helps signal fullness, suppress appetite, and slow gastric emptying. GLP-1 drugs do overlapping jobs through receptors clustered in the gut and the brain. Amylin works on its own receptors. You can stack the signals without simply cranking one dose higher and hoping the side effects stay polite. Perhaps the most interesting aspect is not the extra pounds on a chart. It is the idea that obesity care can stop being a single-pathway bet.

A Hormone That Sat Beside Insulin For Decades

Insulin gets the headlines inside the pancreas. Amylin has always been the quieter roommate. It is co-secreted when blood sugar rises after a meal, then acts as a brake. People with type 1 diabetes, and many with long-standing type 2 diabetes, produce less of it. That missing brake is one reason meals can feel unfinished even when calories are already on board.

I have found that patients rarely ask about the name of the hormone. They ask why they still feel hungry after a plate that used to be enough. Amylin is one answer, not the only one. Ghrelin, leptin, GIP, glucagon, and a crowd of gut peptides all argue at the same table. Drugmakers spent a decade proving that amplifying GLP-1 could move weight in a way older diets could not. The next decade looks like a fight over which second and third voices to invite.

Same outcome, different approach. Fullness is not a single switch. It is a conversation between gut, pancreas, and brain.

Metabolic health researcher, paraphrased from recent clinical commentary

That line is worth sitting with. If fullness is a conversation, a drug that only speaks one language will leave some people half-heard. Combination regimens are the industry’s way of raising its voice without shouting a single receptor into exhaustion.

What The Early Lilly Combination Actually Showed

Lilly’s experimental amylin-targeting drug, eloralintide, was tested with tirzepatide, the active ingredient in its leading obesity and diabetes injections. The Phase 2 trial enrolled people living with both obesity and type 2 diabetes. At 48 weeks, participants on the highest-dose combination lost an average of 23.3 percent of body weight. Those on a high dose of tirzepatide alone lost 14.8 percent. Those figures come from an efficacy analysis that assumes people stayed on treatment.

Read that last clause twice. Efficacy estimands answer a useful question: what happens if someone remains on the medicine? They do not answer the messier question of what happens in a clinic where people quit. Adults with type 2 diabetes typically lose less weight on incretin therapies than adults without diabetes. A gap of roughly eight percentage points, on top of an already solid tirzepatide result, is why analysts sat up. It is also why cautious clinicians did not throw a parade.

The study is still Phase 2. It is relatively small. Phase 3 trials are expected to start later this year, and those trials will have to confirm both the weight change and the day-to-day experience. I’ve found that investors often treat a mid-stage percentage as a destination. Patients treat it as a rumor until a larger study, with a broader mix of bodies and backgrounds, says the same thing.

Tolerability Is The Uncomfortable Number

More people stopped the combination because of side effects. Depending on dose, discontinuation ran from 10.8 percent to 27 percent, against 2.9 percent for tirzepatide alone in the same trial. A senior weight-management physician called 27 percent not a good number. I agree. A medicine that people abandon is a brochure, not a treatment.

Lilly has said it wants later studies to improve how well patients tolerate the paired regimen. That is the right sentence to say. It is also a promise, not a result. Nausea, early fullness, and the odd hollow feeling that comes with slowed gastric emptying already shape who stays on GLP-1 drugs. Adding a second brake can sharpen those effects before the body settles. Dose titration, slower ramps, and smarter pairing will decide whether the combo is a franchise or a footnote.

• Highest-dose combo: about 23.3 percent average weight loss at 48 weeks, on-treatment efficacy view
• High-dose tirzepatide alone: about 14.8 percent in the same analysis
• Combo discontinuations for side effects: 10.8 to 27 percent by dose
• Tirzepatide-only discontinuations for side effects: 2.9 percent
• Population: obesity plus type 2 diabetes, a group that usually loses less

None of those figures are a prescription. They are a sketch. The sketch says the biology can add weight loss. It also says the body sometimes votes no.

Standalone Shot Or Layered Regimen

Lilly is developing eloralintide both alone and inside the combination. Some analysts treat the pair as a future franchise. One sell-side forecast puts annual sales for the eloralintide products near $23.2 billion by the end of 2035, with the standalone drug imagined around 2029 and the combo around 2030. Forecasts that far out are weather reports written in pencil. Still, the split in the forecast is telling. The larger commercial hope, in that view, sits with people who never got what they needed from GLP-1s.

How large is that group? Analysts talk about millions, potentially more than ten million people who tried GLP-1 drugs and left because of weak effect, tolerability, or a genetic pattern that simply does not respond. I would not carve that number in stone. Response is messy. Some people quit for cost. Some quit because the food noise faded and they felt done. Some never started. Even a fraction of that pool is a real market, and a real clinical need.

Company leaders on the cardiometabolic side have made a plainer point. Some patients will not get what they need from tirzepatide. Some will not get what they need from eloralintide alone. The combo is the third door. A plateau after a strong start on tirzepatide is the use case clinicians already recognize. You do not throw out a medicine that worked. You ask whether a second pathway can restart the slope.

Novo’s Longer Head Start With Cagrilintide

Novo has been on this path for years. Its experimental amylin analog, cagrilintide, has produced meaningful weight loss as a standalone treatment in late-stage testing. Paired with semaglutide, the mix known as CagriSema has produced still larger losses in clinical studies. The combination is expected to reach the market early next year, with standalone cagrilintide and a higher-dose version of the combo penciled in for 2028.

Timelines slip. Regulators ask new questions. Manufacturing, pricing, and insurance gates all sit between a positive trial and a prescription pad. Even so, Novo’s sequence is the clearest public map of how an amylin franchise might actually arrive: combo first, solo agent next, then a stronger combo for people who want more effect and can live with the tradeoffs.

Fresh data this week pushed the conversation past the scale. In a yearlong functional brain-imaging study, CagriSema reduced what patients call food noise, the persistent mental loop about the next meal, and was linked with signals of better organ and bone measures. The scans suggested the brain’s response to tempting, high-calorie food shifted in regions tied to craving, pleasure, and self-control. Novo’s scientific leadership framed that shift as something patients feel as quality of life, not just a smaller waist.

If the brain stops treating a pastry like an emergency, daily life gets quieter. That quiet is part of the product, even when it never shows up in a sales slide.

I am wary of brain-scan storytelling. A changed signal is not a changed person. Still, food noise is the complaint I hear more often than “I need eight more percent.” People want the mental chatter to drop. If amylin combinations can do that without asking for a second full-time job of side-effect management, they earn a place that pure weight-loss percentages do not capture.

How Amylin Differs From GLP-1 In Plain Language

Think of appetite as a busy intersection. GLP-1 drugs lengthen the yellow light on one road. Amylin lengthens it on another. Both slow traffic. Neither owns the map. GIP, which tirzepatide already pairs with GLP-1, adjusts insulin response and may soften some gastrointestinal rough edges. Glucagon, added in Lilly’s experimental triple agonist retatrutide, pushes energy expenditure and liver fat in ways the dual agonists do not fully match.

Retatrutide has posted some of the largest weight-loss figures reported in obesity trials so far. Published data also point to substantial drops in liver fat, triglycerides, and fasting insulin. It is too early to declare any amylin combination superior to tirzepatide, retatrutide, or the next dual agonist waiting in someone else’s lab. They still have to clear larger trials and regulatory review. What they share is a design philosophy: more pathways, not just more milligrams of one pathway.

The table is a map, not a ranking. Different bodies will land in different rows. That is the point the companies keep making, and for once the marketing line matches the biology.

Who These Medicines Are Actually For

Not everyone who wants a smaller body needs a second hormone. Some people do well on a single weekly GLP-1, keep the weight off, and move on with their lives. The commercial and clinical case for amylin sits with three overlapping groups.

1. People whose loss on a GLP-1 stalls before health goals are met
2. People who cannot tolerate current doses and need a different mechanism at a gentler intensity
3. People with diabetes, where weight loss from incretins tends to run smaller and metabolic control still matters

There is a fourth group nobody should romanticize: people who were never offered structured nutrition support, sleep help, or a plain conversation about muscle. A new analog will not fix a clinic that only has time for a pen. I’ve found that the best results, even in trial write-ups, show up when the drug is treated as a tool inside a wider routine, not as a personality replacement.

Muscle is the quiet risk. Rapid loss can take lean mass with fat, especially if protein and resistance work are afterthoughts. Bone health showed up in the newer imaging commentary for a reason. Any regimen that pushes loss past 20 percent deserves a plan for strength, not just a celebration of the percentage. That is my bias, and I will keep it.

Pills, Pens, And The Friction Of Staying On

The pipeline is not only injections. Oral versions and combination regimens are part of the same amylin push. A pill sounds easier until you meet the rules: empty stomach, water volume, waiting periods. Some people will trade a weekly needle for a daily ritual. Others will do the reverse. Friction is personal. The winning format is the one a specific person still uses in month fourteen.

Discontinuation is the industry’s open secret. GLP-1 drugs already lose a large share of starters within a year, outside the neat walls of a trial. Cost, shortages, nausea, and the strange grief of a changed appetite all play a part. Amylin combos that raise dropout, even while they raise efficacy, can lose the real-world contest. Phase 3 tolerability is not a footnote. It is the product.

A practical filter before any new regimen:
  Can I eat enough protein?
  Can I train twice a week?
  Can I afford month six?
  Can I name the side effect that would make me stop?

Those four lines are not medical advice. They are the questions I wish more launch presentations included. A drug that only works inside a motivated trial cohort will disappoint the Tuesday afternoon clinic.

The Commercial Shape Of A Second Wave

Obesity medicines already rearranged the valuation of two of the world’s largest drugmakers. A second mechanism does not automatically mean a second fortune. Payers will ask whether an amylin add-on beats a higher dose of something they already cover. They will ask about cardiovascular outcomes, not just pounds. They will ask who should start on a combo and who should switch only after a plateau.

Lilly’s stated path, standalone first around the end of the decade and combo soon after, leaves years of Novo combination data in the market before eloralintide arrives, if those dates hold. First-mover advantage in this category is real, and it is also fragile. A cleaner tolerability profile can steal a launch. A manufacturing miss can hand it back. Pricing that ignores the ten-million-person “tried and left” story will shrink that story to a slogan.

There is also the oral GLP-1 race running in parallel, plus triple agonists, plus smaller biotechs with their own amylin twists. The category is crowding. Crowding is good for patients if it means choice. It is rough for any single sales forecast that assumes a quiet field in 2032.

What Clinicians Will Want Before They Switch

A Phase 2 delta is a conversation starter. Prescribers tend to wait for a few harder items.

• Phase 3 confirmation in both diabetes and non-diabetes obesity
• Clear titration schedules that keep nausea in a livable range
• Data on weight regain after stopping, because most people ask
• Signals on heart, kidney, liver, and bone, not only the scale
• A plain answer on who should not combine pathways

Regain is the question families actually argue about at the table. Current incretin drugs generally require ongoing use to hold the loss. There is no public reason yet to expect amylin analogs to be a short course that rewires appetite forever. Anyone selling them that way is ahead of the evidence. Maintenance, dose reduction, and what “enough” looks like after year two will shape adherence more than the week-48 headline.

Pregnancy, thyroid history, severe gastrointestinal disease, and eating-disorder risk already complicate GLP-1 prescribing. A second anorectic pathway does not simplify those conversations. It adds a line. Good clinics will slow down. Busy clinics may not. That gap worries me more than any single trial percentage.

Food Noise, Cravings, And The Daily Texture Of Care

Weight is the endpoint regulators can count. Food noise is the endpoint patients describe to friends. The imaging work around CagriSema suggested changes in how the brain answered high-calorie cues, in areas linked to wanting, liking, and holding back. If that holds up, amylin combinations are not only metabolic add-ons. They are attention add-ons. Less mental rehearsal of the pantry. More room for everything else.

Is that always a gift? Mostly, yes. Sometimes the sudden quiet feels like a missing limb. People report a flat mood around meals, a loss of ritual, even a strain in relationships built on shared cooking. A good prescriber mentions that before the first pen. A good article should too. Biology that turns down craving can also turn down pleasure. The art is finding a dose where dinner is still dinner.

Diabetes Changes The Math

The Lilly Phase 2 population had obesity and type 2 diabetes. That choice was smart. It is the group that often sees smaller losses on GLP-1 and GIP medicines, and it is a group where glucose, not only weight, pays the bills. An extra eight points of loss, if confirmed, could matter for knees, liver fat, sleep apnea, and the long argument with insulin resistance.

It could also complicate glucose management. Amylin already has a history as an insulin companion, precisely because it alters mealtime glucose excursions. Combining a long-acting amylin analog with a potent incretin means watching for lows in people who still use insulin or sulfonylureas. Trial protocols handle that. Kitchens at 9 p.m. are less tidy. Education has to travel with the pen.

Metabolic specialists have noted for years that insulin resistance is not a single-drug problem. Amylin will not retire metformin, SGLT2 inhibitors, or blood-pressure care. It might sit beside them. The mistake would be treating the new analog as a full replacement for the rest of cardiometabolic medicine. Excess weight is one driver. It is not the only driver.

A Note On Hype, And On Waiting

Every obesity cycle grows a chorus that treats the latest mechanism as the last one. Amylin is not that. It is an additional tool with a plausible biologic story, early human data that look additive, and a tolerability bill that has not been paid yet. Anyone telling you the combo will make GLP-1s obsolete is selling a cleaner narrative than the companies themselves are selling.

The honest version is duller and more useful. Some patients will start on an amylin analog because incretins failed them. Some will add it when a plateau lasts. Some will never need it. A few will not tolerate any of this class and will need surgery, structured programs, or simply time. Variety is the actual goal the drugmakers keep naming. For once, that goal matches what a waiting room looks like.

Signal stack, in plain terms: GLP-1 slows the meal. Amylin confirms the meal happened. GIP tunes the insulin reply. Glucagon spends a bit more fuel. None of them replaces sleep, protein, or a clinic that calls you back.

I like that stack as a mental model. It keeps the drugs in their lane. It also explains why a company would spend a decade on a hormone most people cannot pronounce. The lane was underused.

What Investors And Patients Can Watch Next

The next useful checkpoints are ordinary. Phase 3 starts for the Lilly combo and for standalone eloralintide. Regulatory filing and, if it lands, the first real-world months of CagriSema. Dropout curves, not just press-release percentages. Whether bone and lean-mass substudies are published in full, or tucked into a supplement nobody reads. Pricing letters from large insurers. Supply, because a breakthrough you cannot fill is a rumor with a logo.

Patients can watch something smaller. Do the people who stayed on treatment look like them, or like a narrower slice of the trial? Was diabetes required, or excluded? How fast did the dose rise? A slow ramp that loses two percent of efficacy and keeps twenty percent more people might be the better drug. I would take that trade. Markets sometimes will not, until persistence data forces the issue.

There is a cultural piece too. Obesity medicine spent years fighting the idea that appetite was a moral failing. GLP-1s helped move that argument. Amylin can extend it, if the story stays biological. The moment the marketing implies that anyone who plateaus simply lacked the new hormone, we will have learned nothing. Plateaus have many parents: dose, sleep, muscle loss, cost, depression, a kitchen that did not change.

Putting The Pieces In One Place

So where does this leave a reader who is neither a trialist nor a portfolio manager? With a clearer picture than the headline allows. Amylin is an old signal in a new package. Weekly analogs aim to fix the practical failure of the first generation. Lilly’s early combination with tirzepatide suggests extra loss in people who usually lose less, at the price of more dropouts. Novo’s cagrilintide program is further along as a commercial story, with a combo expected sooner and a brain-imaging hint that food noise can ease.

None of that replaces the medicines already in hand. It argues for a shelf with more than one bottle. Perhaps that is the mature version of this market: less obsession with a single winner, more attention to fit. The ladder that stopped two rungs short might grow another rung. It still will not climb itself.

If you are weighing a future switch, the useful questions are local. What did the current drug already do for glucose, appetite, and joints? What side effect would make month three unbearable? Who will watch muscle while the percentage falls? Those questions age better than any 2035 sales figure. The science is moving. The body keeping the appointment is still the scarce resource.

I will keep an eye on the Phase 3 tolerability tables more closely than on the peak-loss slides. A therapy people remain on is the only therapy that can rewrite a waiting room. Amylin has a real chance to be that therapy for a slice of patients the first wave missed. Chance is not the same as proof. The next two years are where the proof either shows up or does not.